Comerica Bank Sells 4,111 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Comerica Bank decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 9.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,487 shares of the medical research company's stock after selling 4,111 shares during the quarter. Comerica Bank's holdings in IQVIA were worth $7,367,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Norges Bank bought a new stake in IQVIA in the 4th quarter valued at about $336,041,000. Raymond James Financial Inc. bought a new stake in IQVIA in the fourth quarter worth about $236,120,000. American Century Companies Inc. grew its stake in shares of IQVIA by 396.0% in the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock worth $222,987,000 after purchasing an additional 905,960 shares during the last quarter. Invesco Ltd. increased its holdings in shares of IQVIA by 53.4% in the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock valued at $509,012,000 after buying an additional 902,226 shares in the last quarter. Finally, Canada Pension Plan Investment Board boosted its position in shares of IQVIA by 20.0% in the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock valued at $841,461,000 after purchasing an additional 712,958 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of recent analyst reports. Morgan Stanley raised their price objective on shares of IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Royal Bank of Canada reiterated an "outperform" rating and issued a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. Mizuho lowered their price objective on IQVIA from $242.00 to $210.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Citigroup reduced their target price on IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Finally, Stifel Nicolaus dropped their price target on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $231.71.

IQVIA Price Performance

IQV stock traded down $2.43 during midday trading on Friday, reaching $150.86. 627,753 shares of the company's stock traded hands, compared to its average volume of 1,461,352. IQVIA Holdings Inc. has a 1-year low of $135.97 and a 1-year high of $252.88. The company has a market cap of $26.10 billion, a price-to-earnings ratio of 20.11, a PEG ratio of 1.99 and a beta of 1.34. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a 50-day simple moving average of $164.60 and a two-hundred day simple moving average of $189.07.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The company's revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the previous year, the company earned $2.54 EPS. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.